The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2022 | Differential treatment options for left- and right-sided mCRC
Chiara Cremolini, MD, PhD, University of Pisa, Pisa, Italy, provides an overview of therapeutic strategies for patients with RAS wildtype metastatic colorectal cancer (mCRC). Whilst there are novel options for patients with left-sided mCRC including combination therapies consisting of anti-EFGR therapies such as panitumumab with mFOLFOX6, more research is needed to provide efficacious options for patients with right-sided mCRC. Immunotherapy is additionally a viable treatment strategy for patients with microsatellite-instable mCRC. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
